Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.80 |
| ▸ | MMP8 | P22894 | 2/20 | 0.80 |
| ▸ | MMP14 | P50281 | 2/20 | 0.80 |
| ▸ | MMP1 | P03956 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiludronic Acid SCHEMBL18988 | 0.89 | MMP2 (1.00) | MMP2MMP8MMP14MMP1CYP2C9 | |
| Tiludronic Acid SCHEMBL3628467 | 0.88 | MMP2 (0.96) | MMP2MMP8MMP14MMP1CYP2C9 | |
| Tiludronic Acid SCHEMBL8607914 | 0.86 | MMP2 (0.92) | MMP2MMP8MMP14MMP1CYP2C9 | |
| SCHEMBL17954020 | 0.79 | MMP2 (0.79) | MMP2MMP8MMP14MMP1CYP2C9 | |
| Tiludronic Acid SCHEMBL7159094 | 0.78 | MMP2 (0.77) | MMP2MMP8MMP14MMP1CYP2C9 | |
| Tiludronic Acid SCHEMBL2323298 | 0.78 | MMP2 (0.75) | MMP2MMP8MMP14MMP1CYP2C9 | |
| Tiludronic Acid SCHEMBL2326547 | 0.78 | MMP2 (0.75) | MMP2MMP8MMP14MMP1CYP2C9 | |
| Tiludronic Acid SCHEMBL8607912 | 0.77 | MMP2 (0.74) | MMP2MMP8MMP14MMP1CYP2C9 | |
| Tiludronic Acid SCHEMBL9850912 | 0.75 | FDPS (0.51) | MMP2MMP8MMP14MMP1CYP2C9 | |
| Tiludronic Acid SCHEMBL41053 | 0.74 | MMP1 (1.00) | MMP2MMP8MMP14MMP1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174665-A1 | CDK2 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-10266535-B2 | Inhibitor of FLT3 kinase and use thereof | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-23 | — | — | US | disclosed |
| US-20180030054-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2018-02-01 | — | — | US | disclosed |
| EP-2438064-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139731-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174665-A1 | CDK2 INHIBITORS AND USES THEREOF | CDK2, CDK20, CDK1 | MMP2 2855/4885MMP8 3521/4885MMP14 2408/4885 |
| US-20180030054-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | FLT3, FLT1, FGFR1 | MMP2 3227/4885MMP8 4114/4885MMP14 2673/4885 |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | MMP2 1416/4885MMP8 2855/4885MMP14 980/4885 |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | MMP2 1416/4885MMP8 2855/4885MMP14 980/4885 |
| US-10266535-B2 | Inhibitor of FLT3 kinase and use thereof | FLT3, FLT1, FGFR1 | MMP2 3121/4885MMP8 4070/4885MMP14 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.